References
- Arjona R, Riancho JA, Aguado JM, Salesa R, Gonzalez Macias J. Fascioliasis in developed countries: a review of classic and aberrant forms of the diseases. Medicine 1995; 74: 13–23
- Demirci M, Korkmaz M, Kaya S, Kuman A. Fascioliasis in eosinophilic patients in Isparta region of Turkey. Infect 2003; 31: 15–8
- Price TA, Tuazon CA, Simon GL. Fascioliasis: case reports and review. Clin Infec Diseases 1993; 17: 426–30
- Osman MM, Rashwan E, Farag HF. Phagocytic activity of neutrophils in human fascioliasis before and after treatment. J Egypt Soc Parasitol 1995; 25: 321–7
- Weller PF. Human eosinophils. Clinical Immunology 1997; 100: 283–8
- Butterworth AE, Sturrock RF, Houba V, Mahmoud AA, Sher A, Rees PH. Eosinophils as mediators of antibody dependent damage to schistosomula. Nature 1975; 256: 727–9
- Kleine TJ, Gleich GJ, Lewis SA. Eosinophil major basic protein increases membrane permeability in mammalian urinary bladder epithelium. Am J Physiol 1998; 275: 93–103
- Fredens K, Dybdahl H, Dahl R, Baandrup U. Extracellular deposits of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS 1988; 96: 711–9
- Venge P, Bystrom JM, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clinical and Experimental Allergy 1999; 29: 1172–86
- Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucl Acids Res 1998; 26: 3358–63
- Lehrer RI, Szklarez D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Anti-bacterial properties of eosinophil major basic protein (MBP) and eosinophil cationic protein (ECP). J Immunol 1989; 142: 4428–34
- Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986; 321: 613–6
- Carlos Perez C, Vives R, Montes M, Ostiz S. Recurrent eosinophilic panniculitis associated with Fasciola hepatica infection. J Am Acad Dermatol 2000; 42: 900–2
- Shaker ZA, Demerdash ZA, Mansour WA, Hassanein HI, El-Baz HG, Gindy H. Evaluation of specific Fasciola antigen in the immunodiagnosis of human fascioliasis in Egypt. J Egypt Soc Parasitol 1994; 24: 463–70
- Pulpeiro JR, Armesto V, Yesela J, Corredoira J. Fascioliasis: findings in 15 patients. The British J Radiology 1991; 64: 798–801
- Espana A, Sanz ML, Sola J, Gil P. Wells’ syndrome (eosinophilic cellulitis): correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin-5. British Journal of Dermatology 1999; 140: 127–30
- Cox NH, Venge P, Friedmann PS. Eosinophilic cationic protein in dermatitis herpetiformis, bullous pemphigoid, and other blistering disorders. Eur J Dermatol 1993; 3: 294–7
- Czech W, Schaller J, Schopf E, Kapp A. Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 1993; 29: 210–5
- Barck C, Lundahl J, Hallden G, Bylin G. Total eosinophil cationic protein levels in induced sputum as a marker of changes in eosinophilic inflammation in a patient with allergic asthma. Ann Allergy Asthma Immunol 2005; 95: 86–92
- Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of 15 patients with the hypereosinophilic syndrome. Q J Med 1983; 52: 1–22
- De Jesus AR, Silva A, Santana LB, Magalhaes A, De Jesus AA, De Almeida RP, et al. Clinical and immunological evaluation of 31 patients with acute schistosomiasis. J Infect Dis 2002; 185: 98–105
- Koller DY, Gotz M, Eichler I, Urbanek R. Eosinophilic activation in cystic fibrosis. Thorax 1994; 49: 496–9
- Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein-X. Allergy Clin Immunol 1982; 70: 361–6
- Kuberski T. Eosinophils in the cerebrospinal fluid. Ann Intern Med 1979; 91: 70–5